Please use this identifier to cite or link to this item:
Title: Immuno-priming durvalumab with bevacizumab in HER2-negative advanced breast cancer: a pilot clinical trial
Filiation: Servicio de Oncología. Hospital Universitario de Fuenlabrada
Issue Date: 2020
Citation: Breast Cancer Res.2020 11;(22)1:124
Abstract: Preclinical research suggests that the efficacy of immune checkpoint inhibitors in breast cancer can be enhanced by combining them with antiangiogenics, particularly in a sequential fashion. We sought to explore the efficacy and biomarkers of combining the anti-PD-L1 durvalumab plus the antiangiogenic bevacizumab after bevacizumab monotherapy for advanced HER2-negative breast cancer.
PMID: 33176887
Rights: info:eu-repo/semantics/openAccess
Appears in Collections:Hospitales > H. U. de Fuenlabrada > Artículos

Files in This Item:
File Description SizeFormat 
Breast Cancer Research.pdf1.39 MBAdobe PDFThumbnail

This item is licensed under a Creative Commons License Creative Commons